← All trials
NCT02916537
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2016
- Primary completion
- Jul 1, 2017
- Completion date
- Jul 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Cancer Targeted TechnologyLead sponsor
- Cancer Targeted TechnologyStudy chair
- University of California, San FranciscoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.